Andrea Gu: Analyses of whole-genome CRISPR/Cas9 screens identify genetic dependencies in NRAS-mutant melanoma
posterposted on 30.09.2021, 06:07 by Andrea GuAndrea Gu
Melanoma ranks the third most common cancer in New Zealand. Mutations in NRAS are found in approximately 20% of melanoma cases, yet there is no effective treatment specifically for NRAS-mutant melanoma. The identification of genetic dependencies alongside NRAS mutations may provide novel drug targets for the treatment of NRAS-mutant melanoma.
This poster was uploaded for the SGS Research Showcase 2021.Choose your favourite poster to win the People's Choice Award at the 2021 SGS Research Showcase: https://auckland.au1.qualtrics.com/jfe/form/SV_9Fw8Omf43pstYUu